Hasbro Inc
Leisure Products
Hasbro Inc (HAS) Stock News
The latest HAS headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
FERRARI N.V.: COMPLETION OF THE SECOND TRANCHE AND ANNOUNCEMENT OF THE THIRD TRANCHE OF THE MULTI-YEAR SHARE REPURCHASE PROGRAM
Ferrari N.V. has completed its €250 million second tranche of share buybacks, purchasing 815,739 common shares across Euronext Milan and NYSE for €249.999 million. The company announced a third tranche of up to €250 million starting September 2, 2026, to be executed through non-discretionary agreements with primary financial institutions. Since January 2026, Ferrari has repurchased 1,701,184 shares totaling €510.76 million as part of its €3.5 billion multi-year buyback program expected to conclude by 2030.
- Zacks Investment Research·
BFH or HASI: Which Is the Better Value Stock Right Now?
A comparison of two Financial - Miscellaneous Services sector stocks reveals that Bread Financial Holdings (BFH) presents a better value opportunity than HA Sustainable Infrastructure Capital (HASI). BFH holds a Zacks Rank #1 (Strong Buy) with improving earnings outlook and a Value grade of B, supported by a lower forward P/E ratio of 8.63 and PEG ratio of 0.66. HASI has a Zacks Rank #3 (Hold) with a Value grade of D, featuring a higher forward P/E of 12.98 and PEG ratio of 1.15.
- GlobeNewswire Inc.·
FSI ANNOUNCES THE COMPANY HAS TRADED EQUITY IN THE FLORIDA LLC FOR EXCLUSIVE PRODUCT RIGHTS
Flexible Solutions International (FSI) announced it has traded its remaining 19.9% stake in FL LLC to recover exclusive rights to manufacture and sell four agricultural products across Latin America, Central America, the Caribbean, and South America. The move follows an acquirer's failure to meet payment obligations on a previous 30.1% equity sale. CEO Dan O'Brien expects significant revenue recovery in the second half of 2026.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.
- Benzinga·
KEYCORP DECLARES QUARTERLY CASH DIVIDEND ON COMMON SHARES AND PREFERRED STOCKS AND ANNOUNCES NEW SHARE REPURCHASE PROGRAM
KeyCorp announced a quarterly cash dividend of $0.205 per share on common stock payable June 15, 2026, along with dividends on multiple preferred stock series. The company also authorized a new $3.0 billion share repurchase program, replacing its previous $1.0 billion authorization with approximately $280 million remaining.